The global infectious disease rapid diagnostics devices market is experiencing strong growth as healthcare systems increasingly prioritize early detection, quick decision-making, and efficient disease management. Rapid diagnostic devices enable healthcare providers to identify infectious diseases within minutes or hours, significantly improving patient outcomes and reducing the spread of infections.

The global infectious disease rapid diagnostics devices market was valued at US$ 9.7 Billion in 2024 and is projected to cross US$ 20.2 Billion by the end of 2035, expanding at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2035. The increasing prevalence of infectious diseases, rising demand for point-of-care testing, and advancements in diagnostic technologies are key drivers supporting market growth.

Get your sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86762

Market Overview

Infectious disease rapid diagnostic devices are designed to detect pathogens such as bacteria, viruses, and parasites quickly and accurately. These devices are widely used in hospitals, diagnostic laboratories, clinics, and home care settings.

Common technologies used in rapid diagnostics include lateral flow assays, molecular diagnostics, immunoassays, and nucleic acid amplification tests (NAATs). These tools provide fast results, enabling timely treatment decisions and reducing reliance on time-consuming laboratory procedures.

Rapid diagnostics play a critical role in managing diseases such as COVID-19, influenza, HIV, malaria, tuberculosis, and dengue, making them essential in modern healthcare systems.

Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases worldwide is one of the primary factors driving the demand for rapid diagnostic devices. Factors such as urbanization, global travel, climate change, and emerging pathogens are contributing to the spread of infectious diseases.

Early detection is crucial for effective treatment and preventing outbreaks. Rapid diagnostic devices allow healthcare providers to quickly identify infections and implement appropriate treatment strategies, reducing the burden on healthcare systems.

Growing Demand for Point-of-Care Testing

Point-of-care (POC) testing is gaining significant traction as healthcare providers seek faster and more convenient diagnostic solutions. Rapid diagnostic devices enable testing at or near the patient site, eliminating the need for centralized laboratory testing.

POC testing is particularly valuable in remote and resource-limited settings, where access to advanced laboratory infrastructure may be limited. It also enhances patient convenience and reduces turnaround time for results.

Technological Advancements in Diagnostic Devices

Continuous innovation in diagnostic technologies is transforming the infectious disease rapid diagnostics market. Advances in molecular diagnostics, biosensors, microfluidics, and artificial intelligence (AI) are improving the accuracy, sensitivity, and speed of diagnostic devices.

Modern rapid diagnostic devices are becoming more compact, user-friendly, and capable of detecting multiple pathogens simultaneously. Integration with digital health platforms is also enabling real-time data sharing and remote monitoring.

Increasing Government Initiatives and Healthcare Investments

Governments and healthcare organizations around the world are investing in diagnostic infrastructure to strengthen healthcare systems and improve disease management. Public health initiatives aimed at controlling infectious diseases are driving the adoption of rapid diagnostic devices.

Funding for research and development, along with regulatory support for innovative diagnostic technologies, is further contributing to market growth. The lessons learned from global health crises have accelerated investments in rapid testing capabilities.

Key Developments in Infectious Disease Rapid Diagnostics Devices Market

• In July 2025, Seegene Inc. announced the launch of STAgora, the next-generation infectious disease analytics platform. As a real-time infectious disease intelligence platform, the product has integrated diagnostic data with sophisticated statistical modeling and has the intent to redefine the detection, tracking, and response to outbreaks globally.
• In January 2024, QIAGEN launched two syndromic test panels for its QIAstat-Dx systems in India – the Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel, in addition to the Respiratory SARS-CoV-2 Panel that had been approved for emergency use for the first time in 2020.

Get this premium report for strategic insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=86762&ltype=S

Regional Analysis

North America

North America holds a dominant share of the global market due to advanced healthcare infrastructure, high adoption of diagnostic technologies, and strong presence of key market players. The United States leads the region with extensive use of rapid diagnostic devices in hospitals, clinics, and home care settings.

Europe

Europe is a significant market driven by increasing demand for early disease detection and strong healthcare systems. Countries such as Germany, the United Kingdom, and France are investing in advanced diagnostic technologies and public health programs.

Asia Pacific

Asia Pacific is expected to witness the fastest growth during the forecast period due to rising population, increasing healthcare awareness, and improving healthcare infrastructure. Countries such as China, India, Japan, and South Korea are expanding access to diagnostic services and investing in healthcare innovation.

Latin America and Middle East & Africa

These regions are gradually growing due to increasing healthcare investments and rising awareness of infectious disease management. Efforts to improve access to diagnostic tools in underserved areas are supporting market expansion.

Key Companies in the Infectious Disease Rapid Diagnostics Devices Market

The global market is highly competitive, with major companies focusing on innovation, product development, and strategic collaborations. Key players include:

• F. Hoffmann-La Roche AG
• Abbott
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Diasorin S.p.A.
• Hologic, Inc.
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Seegene Inc.
• QIAGEN
• Danaher Corporation
• Trinity Biotech
• Grifols

These companies are actively developing advanced diagnostic solutions to enhance speed, accuracy, and accessibility.

Market Challenges

Despite strong growth prospects, the market faces challenges such as accuracy limitations in some rapid tests, regulatory complexities, and pricing pressures. Inconsistent performance in low-resource settings and concerns over false results may impact adoption.

Additionally, the need for continuous innovation and compliance with stringent regulatory standards can increase development costs for manufacturers.

Future Outlook

The infectious disease rapid diagnostics devices market is expected to grow steadily as healthcare systems continue to prioritize early detection and efficient disease management. Technological advancements, increasing demand for point-of-care testing, and rising healthcare investments will drive market expansion.

With the market projected to cross US$ 20.2 Billion by 2035, rapid diagnostic devices will remain essential tools in combating infectious diseases and improving global health outcomes.

Frequently Asked Questions (FAQs)

Q1. What is the projected size of the infectious disease rapid diagnostics devices market by 2035?
The market is expected to exceed US$ 20.2 Billion by the end of 2035.

Q2. What is the expected CAGR of the market?
The market is projected to grow at a CAGR of 6.9% from 2025 to 2035.

Q3. What are the key drivers of the market?
Key drivers include rising prevalence of infectious diseases, growing demand for point-of-care testing, technological advancements, and increasing healthcare investments.

Q4. Which region dominates the market?
North America holds a dominant share due to advanced healthcare infrastructure and high adoption of diagnostic technologies.

Q5. What are common applications of rapid diagnostic devices?
They are used for detecting COVID-19, influenza, HIV, malaria, tuberculosis, and other infectious diseases.

More Trending Research Reports-

Food Processing Equipment Market: https://www.transparencymarketresearch.com/food-processing-equipment-market.html

Polyvinylpyrrolidone (PVP) Market: https://www.transparencymarketresearch.com/polyvinylpyrrolidone-market.html

Air Purification Systems Market: https://www.transparencymarketresearch.com/air-purification-systems-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453